Company news

Palisade Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts

May 23, 2023

Palisade Bio Reports First Quarter 2023 Financial Results

May 11, 2023

Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

May 10, 2023

Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

April 5, 2023

Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148

April 4, 2023

Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

April 2, 2023

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

March 22, 2023

Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent

February 28, 2023

Palisade Bio Promotes Robert McRae to Chief Operating Officer

February 7, 2023

Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million

January 9, 2023

Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

December 29, 2022

Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

December 15, 2022

Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

December 6, 2022

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

November 30, 2022

Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery

November 21, 2022

Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer

November 17, 2022

Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video

November 16, 2022

Palisade Bio Announces Reverse Stock Split

November 14, 2022

Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

Palisade Bio Announces Executive Leadership Transition

October 10, 2022

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022

September 28, 2022

Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 22, 2022

Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148

September 14, 2022

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

August 16, 2022

Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option

August 15, 2022

Palisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 14, 2022

Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

August 11, 2022

Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health

July 31, 2022

Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

July 26, 2022

Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

June 28, 2022

Palisade Bio to Present at the 2022 BIO International Convention

June 6, 2022

Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires

May 9, 2022

Palisade Bio Announces $2.0 Million Registered Direct Offering

May 5, 2022

Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

May 4, 2022

Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements

May 1, 2022

Palisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

March 21, 2022

Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update

March 17, 2022

Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

March 15, 2022

Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus

December 7, 2021

Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035

November 29, 2021

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Including Nick McCoy, Vice President of Clinical Operations

November 22, 2021

Palisade Bio Reports Third Quarter Financial Results

November 14, 2021

Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders

October 21, 2021

Palisade Bio Reports Second Quarter Financial Results and Provides Business Update

August 23, 2021

Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center

August 19, 2021

Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery

July 28, 2021

Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development

July 12, 2021

Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions

June 14, 2021

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

May 12, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 42 decks. Every deck is listed under its year.